Treatment of chronic myeloid leukemia in the imatinib era : Perspective from a developing country
There is paucity of data from developing countries on the efficacy and safety of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study was to document complete and partial cytogenetic responses to imatinib in all phases of CML. Secondary objectives included evaluat...
Gespeichert in:
| Veröffentlicht in: | Cancer 2007-03, Vol.109 (6), p.1138-1145 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1145 |
|---|---|
| container_issue | 6 |
| container_start_page | 1138 |
| container_title | Cancer |
| container_volume | 109 |
| creator | AZIZ, Zeba IQBAL, Javaid AKRAM, Mohammad SAEED, Sarah |
| description | There is paucity of data from developing countries on the efficacy and safety of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study was to document complete and partial cytogenetic responses to imatinib in all phases of CML. Secondary objectives included evaluations of complete hematologic response, safety, time to progression, and survival.
Two hundred seventy-five patients in all phases of CML who received treatment with imatinib from January 2001 to December 2005 were included in the study. All patients had on bone marrow or BCR-ABL positive in peripheral blood by polymerase chain reaction.
After a median follow-up of 18 months, major cytogenetic responses (Ph |
| doi_str_mv | 10.1002/cncr.22498 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_cncr_22498</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17315159</sourcerecordid><originalsourceid>FETCH-LOGICAL-c274t-a7c13d2772aa67134021d635f388a619b7bef38edd95503df9649c4dae95491a3</originalsourceid><addsrcrecordid>eNpFkE1LAzEQhoMotlYv_gDJxYuwNZ-bjTcpfkFBDxW8Ldlk1kZ3syXZFvrv3dpCTzMDz7y8PAhdUzKlhLB7G2ycMiZ0cYLGlGiVESrYKRoTQopMCv41Qhcp_QynYpKfoxFVnEoq9RiZRQTTtxB63NXYLmMXvMXtFprOO9zA-hdab7APuF8C9q3pffAVhmjwA_6AmFZge78BXMeuxQY72AyvKx--se3WoY_bS3RWmybB1WFO0Ofz02L2ms3fX95mj_PMMiX6zChLuWNKMWNyRbkgjLqcy5oXhcmprlQFww7OaSkJd7XOhbbCGdBSaGr4BN3tc23sUopQl6s49I3bkpJy56nceSr_PQ3wzR5erasW3BE9iBmA2wNgkjVNHU2wPh25QhZSFpr_AQCScUk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment of chronic myeloid leukemia in the imatinib era : Perspective from a developing country</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>AZIZ, Zeba ; IQBAL, Javaid ; AKRAM, Mohammad ; SAEED, Sarah</creator><creatorcontrib>AZIZ, Zeba ; IQBAL, Javaid ; AKRAM, Mohammad ; SAEED, Sarah</creatorcontrib><description>There is paucity of data from developing countries on the efficacy and safety of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study was to document complete and partial cytogenetic responses to imatinib in all phases of CML. Secondary objectives included evaluations of complete hematologic response, safety, time to progression, and survival.
Two hundred seventy-five patients in all phases of CML who received treatment with imatinib from January 2001 to December 2005 were included in the study. All patients had on bone marrow or BCR-ABL positive in peripheral blood by polymerase chain reaction.
After a median follow-up of 18 months, major cytogenetic responses (Ph <35%) in chronic phase (CP), accelerated phase (AP), and blastic phase (BP) were documented in 61%, 57%, and 28% of patients, respectively. A complete cytogenetic response was observed in 39.4%, 35.7%, and 14.3% of patients in CP, AP, and BP, respectively; and a complete hematologic response was observed in 90%, 86%, and 30%, respectively. The median time to progression at 18 months was 91% in CP and 68% in AP. The overall survivals in CP, AP, and BP at 18 months was 92%, 74%, and 38%, respectively.
Impressive hematologic, cytogenetic, and molecular responses to imatinib were observed, similar to the responses reported in patients from Western countries. Patients had good compliance, toxicity was limited, and overall quality of life was improved markedly. The results indicated that the biology of CML is not different in patients from developing countries.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.22498</identifier><identifier>PMID: 17315159</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York, NY: Wiley-Liss</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Benzamides ; Biological and medical sciences ; Child ; Cytogenetic Analysis ; Developing Countries ; Female ; Hematologic and hematopoietic diseases ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Pakistan - epidemiology ; Piperazines - therapeutic use ; Pyrimidines - therapeutic use ; Quality of Life ; Treatment Outcome ; Tumors</subject><ispartof>Cancer, 2007-03, Vol.109 (6), p.1138-1145</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c274t-a7c13d2772aa67134021d635f388a619b7bef38edd95503df9649c4dae95491a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18585589$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17315159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>AZIZ, Zeba</creatorcontrib><creatorcontrib>IQBAL, Javaid</creatorcontrib><creatorcontrib>AKRAM, Mohammad</creatorcontrib><creatorcontrib>SAEED, Sarah</creatorcontrib><title>Treatment of chronic myeloid leukemia in the imatinib era : Perspective from a developing country</title><title>Cancer</title><addtitle>Cancer</addtitle><description>There is paucity of data from developing countries on the efficacy and safety of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study was to document complete and partial cytogenetic responses to imatinib in all phases of CML. Secondary objectives included evaluations of complete hematologic response, safety, time to progression, and survival.
Two hundred seventy-five patients in all phases of CML who received treatment with imatinib from January 2001 to December 2005 were included in the study. All patients had on bone marrow or BCR-ABL positive in peripheral blood by polymerase chain reaction.
After a median follow-up of 18 months, major cytogenetic responses (Ph <35%) in chronic phase (CP), accelerated phase (AP), and blastic phase (BP) were documented in 61%, 57%, and 28% of patients, respectively. A complete cytogenetic response was observed in 39.4%, 35.7%, and 14.3% of patients in CP, AP, and BP, respectively; and a complete hematologic response was observed in 90%, 86%, and 30%, respectively. The median time to progression at 18 months was 91% in CP and 68% in AP. The overall survivals in CP, AP, and BP at 18 months was 92%, 74%, and 38%, respectively.
Impressive hematologic, cytogenetic, and molecular responses to imatinib were observed, similar to the responses reported in patients from Western countries. Patients had good compliance, toxicity was limited, and overall quality of life was improved markedly. The results indicated that the biology of CML is not different in patients from developing countries.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Cytogenetic Analysis</subject><subject>Developing Countries</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pakistan - epidemiology</subject><subject>Piperazines - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Quality of Life</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LAzEQhoMotlYv_gDJxYuwNZ-bjTcpfkFBDxW8Ldlk1kZ3syXZFvrv3dpCTzMDz7y8PAhdUzKlhLB7G2ycMiZ0cYLGlGiVESrYKRoTQopMCv41Qhcp_QynYpKfoxFVnEoq9RiZRQTTtxB63NXYLmMXvMXtFprOO9zA-hdab7APuF8C9q3pffAVhmjwA_6AmFZge78BXMeuxQY72AyvKx--se3WoY_bS3RWmybB1WFO0Ofz02L2ms3fX95mj_PMMiX6zChLuWNKMWNyRbkgjLqcy5oXhcmprlQFww7OaSkJd7XOhbbCGdBSaGr4BN3tc23sUopQl6s49I3bkpJy56nceSr_PQ3wzR5erasW3BE9iBmA2wNgkjVNHU2wPh25QhZSFpr_AQCScUk</recordid><startdate>20070315</startdate><enddate>20070315</enddate><creator>AZIZ, Zeba</creator><creator>IQBAL, Javaid</creator><creator>AKRAM, Mohammad</creator><creator>SAEED, Sarah</creator><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20070315</creationdate><title>Treatment of chronic myeloid leukemia in the imatinib era : Perspective from a developing country</title><author>AZIZ, Zeba ; IQBAL, Javaid ; AKRAM, Mohammad ; SAEED, Sarah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c274t-a7c13d2772aa67134021d635f388a619b7bef38edd95503df9649c4dae95491a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Cytogenetic Analysis</topic><topic>Developing Countries</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pakistan - epidemiology</topic><topic>Piperazines - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Quality of Life</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>AZIZ, Zeba</creatorcontrib><creatorcontrib>IQBAL, Javaid</creatorcontrib><creatorcontrib>AKRAM, Mohammad</creatorcontrib><creatorcontrib>SAEED, Sarah</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>AZIZ, Zeba</au><au>IQBAL, Javaid</au><au>AKRAM, Mohammad</au><au>SAEED, Sarah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of chronic myeloid leukemia in the imatinib era : Perspective from a developing country</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2007-03-15</date><risdate>2007</risdate><volume>109</volume><issue>6</issue><spage>1138</spage><epage>1145</epage><pages>1138-1145</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>There is paucity of data from developing countries on the efficacy and safety of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study was to document complete and partial cytogenetic responses to imatinib in all phases of CML. Secondary objectives included evaluations of complete hematologic response, safety, time to progression, and survival.
Two hundred seventy-five patients in all phases of CML who received treatment with imatinib from January 2001 to December 2005 were included in the study. All patients had on bone marrow or BCR-ABL positive in peripheral blood by polymerase chain reaction.
After a median follow-up of 18 months, major cytogenetic responses (Ph <35%) in chronic phase (CP), accelerated phase (AP), and blastic phase (BP) were documented in 61%, 57%, and 28% of patients, respectively. A complete cytogenetic response was observed in 39.4%, 35.7%, and 14.3% of patients in CP, AP, and BP, respectively; and a complete hematologic response was observed in 90%, 86%, and 30%, respectively. The median time to progression at 18 months was 91% in CP and 68% in AP. The overall survivals in CP, AP, and BP at 18 months was 92%, 74%, and 38%, respectively.
Impressive hematologic, cytogenetic, and molecular responses to imatinib were observed, similar to the responses reported in patients from Western countries. Patients had good compliance, toxicity was limited, and overall quality of life was improved markedly. The results indicated that the biology of CML is not different in patients from developing countries.</abstract><cop>New York, NY</cop><pub>Wiley-Liss</pub><pmid>17315159</pmid><doi>10.1002/cncr.22498</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2007-03, Vol.109 (6), p.1138-1145 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_cncr_22498 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Child Cytogenetic Analysis Developing Countries Female Hematologic and hematopoietic diseases Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Pakistan - epidemiology Piperazines - therapeutic use Pyrimidines - therapeutic use Quality of Life Treatment Outcome Tumors |
| title | Treatment of chronic myeloid leukemia in the imatinib era : Perspective from a developing country |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A39%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20chronic%20myeloid%20leukemia%20in%20the%20imatinib%20era%20:%20Perspective%20from%20a%20developing%20country&rft.jtitle=Cancer&rft.au=AZIZ,%20Zeba&rft.date=2007-03-15&rft.volume=109&rft.issue=6&rft.spage=1138&rft.epage=1145&rft.pages=1138-1145&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.22498&rft_dat=%3Cpubmed_cross%3E17315159%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17315159&rfr_iscdi=true |